Using ACY-1215 treatment (a selective HDAC6 inhibitor that has successfully passed a phase-Ib clinical trial for refractory multiple myeloma [44]), we observed a significant tumor growth inhibition in xenograft models. This evidence concerns the gene HDAC6 and neoplasm.